Ishita drugs & indus has disclosed a share acquisition by its related party under SEBI regulations. Ishita Pharmaceuticals, identified as a related party of the target company, acquired 506 equity shares of Rs. 10 each on February 24, 2026. The transaction was conducted through open market purchase and disclosed under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Transaction Details

The acquisition involved a modest purchase of shares that marginally increased Ishita Pharmaceuticals' stake in the company. The disclosure was filed with BSE Limited, where Ishita Drugs & Industries shares are listed under scrip code 524400.

Shareholding Changes

The acquisition resulted in a minor increase in Ishita Pharmaceuticals' ownership percentage. Prior to this transaction, the related party held 31,746 shares representing 1.06% of the total share capital. Post-acquisition, the holding increased to 32,252 shares, representing 1.08% of the company's equity.

Company Capital Structure

The target company's equity share capital remained unchanged following this acquisition. Ishita Drugs & Industries maintains its total equity share capital at Rs. 29,903,000, divided into 2,990,300 equity shares of Rs. 10 each. The diluted share capital also remains at the same level, indicating no outstanding convertible securities or warrants.

Regulatory Compliance

Both Ishita Drugs & Industries and Ishita Pharmaceuticals filed the necessary disclosures with BSE Limited as required under SEBI regulations. The disclosure format included comprehensive details about the acquirer's holdings before and after the transaction, acquisition mode, and the target company's capital structure. The related party status of Ishita Pharmaceuticals was clearly identified in the regulatory filing, ensuring transparency in the transaction disclosure.

Ishita drugs & indus and Industries Limited has submitted a regulatory disclosure under SEBI's substantial acquisition and takeover regulations. The filing, digitally signed by key personnel, outlines details of a corporate transaction involving share acquisition.

Transaction Details

The disclosure filed under Regulation 29(2) of SEBI (Substantial Acquisition and Takeovers) Regulations, 2011, identifies the following key parties and parameters:

Share Holdings Information

The regulatory filing includes details about share holdings before the acquisition under consideration. The document mentions 30,550 shares in the context of the transaction structure.

Regulatory Compliance

The disclosure document bears digital signatures from Abha Jagdishprasad Agrawal and Sumit Jagdishprasad Agrawal, dated February 14, 2026. The filing demonstrates the company's adherence to SEBI's transparency requirements for substantial acquisitions and takeovers.

Company Operations

Ishita Pharmaceuticals, identified as the acquirer, operates with contact details including phone number 91-79-26468353/886 and email ishitapharmal980@gmail.com . The company maintains a factory facility at 65/1, GIDC Industrial Estate, Wadhwan-363035, Surendranagar, India.

This regulatory disclosure ensures compliance with SEBI's substantial acquisition regulations and provides transparency to stakeholders regarding the corporate transaction involving the listed entity.